Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRAX Stock Forecast 2025-2026
$1.07
Current Price
$4.69M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VRAX Price Targets
+180.5%
To High Target of $3.00
+180.5%
To Median Target of $3.00
+180.5%
To Low Target of $3.00
VRAX Price Momentum
+1.9%
1 Week Change
+8.1%
1 Month Change
+27.4%
1 Year Change
-52.4%
Year-to-Date Change
-88.1%
From 52W High of $9.00
+42.6%
From 52W Low of $0.75
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Virax Biolabs (VRAX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VRAX and similar high-potential opportunities.
Latest VRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, VRAX has a bullish consensus with a median price target of $3.00 (ranging from $3.00 to $3.00). Currently trading at $1.07, the median forecast implies a 180.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 180.5% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 180.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRAX Analyst Ratings
1
Buy
0
Hold
0
Sell
VRAX Price Target Range
Low
$3.00
Average
$3.00
High
$3.00
Current: $1.07
Latest VRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $3.00 |
Virax Biolabs Group Ltd. (VRAX) Competitors
The following stocks are similar to Virax Biolabs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Virax Biolabs Group Ltd. (VRAX) Financial Data
Virax Biolabs Group Ltd. has a market capitalization of $4.69M with a P/E ratio of 0.0x. The company generates $84,872 in trailing twelve-month revenue with a 32.3% profit margin.
Revenue growth is -93.5% quarter-over-quarter, while maintaining an operating margin of -58,112.5% and return on equity of -90.6%.
Valuation Metrics
Market Cap
$4.69M
Enterprise Value
$-2,317,141
P/E Ratio
0.0x
PEG Ratio
-0.6x
Price/Sales
55.3x
Growth & Margins
Revenue Growth (YoY)
-93.5%
Gross Margin
N/A
Operating Margin
-58,112.5%
Net Margin
+32.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+159.0%
Current Ratio
11.6x
Debt/Equity
7.2x
ROE
-90.6%
ROA
-47.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Virax Biolabs Group Ltd. (VRAX) Business Model
About Virax Biolabs Group Ltd.
What They Do
Develops diagnostic testing kits for viral diseases.
Business Model
Virax Biolabs generates revenue by creating and distributing diagnostic testing kits aimed at the detection and management of viral diseases. Their primary customers include healthcare institutions, government health departments, and research organizations, ensuring a diverse revenue stream that supports public health initiatives.
Additional Information
The company's products are essential during global health crises, enhancing public health surveillance and response capabilities. Virax Biolabs emphasizes the importance of advancing medical diagnostics to improve community health and well-being.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. James Foster
Country
United Kingdom
IPO Year
2022
Website
viraxbiolabs.comVirax Biolabs Group Ltd. (VRAX) Latest News & Analysis
Latest News
Quick Summary
H.C. Wainwright has started coverage on Virax Biolabs Group Limited (VRAX), a U.K. company specializing in detecting immune responses and diagnosing viral diseases.
Why It Matters
H.C. Wainwright's coverage initiation on Virax Biolabs signals potential growth and investment interest in the biotech sector, impacting stock valuation and investor sentiment.
Source: Benzinga
Market Sentiment:
Positive
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
2 months ago
Quick Summary
Virax Biolabs (NASDAQ: VRAX) has begun patient enrollment for a UK clinical study on its ViraxImmune™ assay, targeting T cell dysfunction in post-acute infection syndrome, including long COVID.
Why It Matters
The start of patient enrollment for a clinical study on Virax's T cell assay could signal potential advancements in treatment options, impacting stock performance and investor sentiment in biotech.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs presented data on T-Cell dysfunction related to post-acute infection syndromes at the World Immune Regulation Meeting in Davos, highlighting its focus on viral disease diagnostics.
Why It Matters
Virax's presentation on T-Cell dysfunction in post-acute infection syndromes highlights its innovative research, potentially boosting market confidence and influencing stock performance in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs (Nasdaq: VRAX) will present at the 19th World Immune Regulation Meeting in Davos, Switzerland, from March 12-15, showcasing its immune profiling products.
Why It Matters
Virax Biolabs' presentation at a major conference highlights its innovative research, potentially boosting credibility and interest, influencing stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs Group (NASDAQ: VRAX) focuses on vaccine efficacy testing and immune profile data, aligning with U.S. health initiatives to enhance transparency in vaccination decisions.
Why It Matters
Virax Biolabs' alignment with U.S. health initiatives on vaccine efficacy enhances its market credibility, potentially boosting demand for its technology and positively impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cosmos Health Inc. (NASDAQ:COSM) has signed a supplemental agreement to exclusively distribute Virax-branded Avian Influenza Virus PCR Kits in GCC countries, expanding from Oman and Bahrain to include Saudi Arabia, UAE, Qatar, and Kuwait.
Why It Matters
Cosmos Health's expanded distribution agreement enhances its market reach in the GCC, potentially boosting revenues and strengthening its position in the healthcare sector.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About VRAX Stock
What is Virax Biolabs Group Ltd.'s (VRAX) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Virax Biolabs Group Ltd. (VRAX) has a median price target of $3.00. The highest price target is $3.00 and the lowest is $3.00.
Is VRAX stock a good investment in 2025?
According to current analyst ratings, VRAX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRAX stock?
Wall Street analysts predict VRAX stock could reach $3.00 in the next 12 months. This represents a 180.5% increase from the current price of $1.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Virax Biolabs Group Ltd.'s business model?
Virax Biolabs generates revenue by creating and distributing diagnostic testing kits aimed at the detection and management of viral diseases. Their primary customers include healthcare institutions, government health departments, and research organizations, ensuring a diverse revenue stream that supports public health initiatives.
What is the highest forecasted price for VRAX Virax Biolabs Group Ltd.?
The highest price target for VRAX is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 180.5% increase from the current price of $1.07.
What is the lowest forecasted price for VRAX Virax Biolabs Group Ltd.?
The lowest price target for VRAX is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 180.5% increase from the current price of $1.07.
What is the overall VRAX consensus from analysts for Virax Biolabs Group Ltd.?
The overall analyst consensus for VRAX is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are VRAX stock price projections?
Stock price projections, including those for Virax Biolabs Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 11:44 AM UTC